178
Participants
Start Date
September 24, 2015
Primary Completion Date
October 24, 2024
Study Completion Date
October 24, 2024
Lifileucel
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
Inselspital, Bern
Universitätsklinikum Leipzig, Leipzig
Szegedi Tudomanyegyetem Szent-Györgyi Albert Klinikai Központ, Szeged
New York University Langone Medical Center, New York
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia, Candiolo
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Istituto Europeo di Oncologia, Milan
Virginia Commonwealth University, Richmond
Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck
Hospital General Universitario Gregorio Marañon, Madrid
Hospital 12 de Octubre, Madrid
HM Centro Integral Oncológico Clara Campal, Madrid
Hospital Universitario Quirónsalud Madrid, Madrid
Clínica Universidad de Navarra, Pamplona
University of Florida Health Cancer Center, Orlando
Centro di Riferimento Oncologico di Aviano, Aviano
University of Miami, Miami
Mount Sinai Comprehensive Cancer Center, Miami Beach
University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa
James Graham Brown Cancer Center, Louisville
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Medical College of Wisconsin, Milwaukee
University of Minnesota, Masonic Cancer Center, Minneapolis
Centre Léon Bérard, Lyon
Universitaetsklinikum Heidelberg, Heidelberg
Centre Hospitalier Lyon Sud, Pierre-Bénite
Universitaetsklinikum Tuebingen (UKT) - Suedwestdeutschen Tumorzentrum - Zentrum für Neuroonkologie, Tübingen
University of Colorado Cancer Center, Aurora
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli
Klinikum Rechts der Isar der Technischen Universität München, München
Hôpital Dupuytren, Limoges
The Angeles Clinic and Research Institute, Los Angeles
University of California Los Angeles - David Geffen School of Medicine - Westwood Rheumatology, Los Angeles
Universitätsklinikum Erlangen, Erlangen
University of California San Diego Moores Cancer Center, La Jolla
California Pacific Medical Center, San Francisco
Gustave Roussy Cancer Campus, Villejuif
Universitätsklinikum Würzburg, Würzburg
Providence Cancer Center Oncology and Hematology Care Clinic, Portland
Seattle Cancer Care Alliance, Seattle
Yale Cancer Center, New Haven
Indiana University, Indianapolis
Atlantic Health System, Morristown
Rutgers University, New Brunswick
Universitätsklinikum Carl Gustav Carus, Dresden
Consorci Hospital General Universitari de València, Valencia
Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie, Lausanne
Universitätsklinikum Halle, Halle
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Clinic de Barcelona, Barcelona
Institut Català d'Oncologia, Barcelona
Royal Marsden NHS Trust, London
Beatson West of Scotland Cancer Centre, Glasgow
Addenbrooke's Hospital, Cambridge
Sarah Cannon Research Institute London, London
Lead Sponsor
Iovance Biotherapeutics, Inc.
INDUSTRY